InvestorsHub Logo
Followers 164
Posts 36254
Boards Moderated 2
Alias Born 10/20/2019

Re: StockHighAlert- post# 553

Wednesday, 02/16/2022 11:09:48 AM

Wednesday, February 16, 2022 11:09:48 AM

Post# of 667
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.

AVA-011 is currently at the IND-enabling process development stage.

The platform uses next-generation CAR technology to modify patients' T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing the cell therapy products.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ALBT News